PHENOTYPIC SCREENING
mRNA IMAGES
mRNA LIFE CYCLE
THE MECHANISM OF ACTION
Anima Biotech mRNA Lightning™ Platform
We are advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using AI to elucidate the mechanism of action of active molecules. We develop our own pipeline and partner with pharma on additional targets.
A unique approach at the intersection of mRNA biology and Artificial Intelligence
mRNA Lightning™ Platform
Discovery of small molecule mRNA drugs and their mechanisms of action with automated high scale phenotypic screening in live mRNA biology and MOAi technology that uses AI to elucidate the mechanism of action of active molecules.
Discovery of mRNA biology modulators
Anima's discovery process for mRNA biology modulators relies on our proprietary interconnected technologies.
Lightning-Gene runs to produce an in-depth analysis of the mRNA of interest and selects its signature tRNA pair that enables us to visualize mRNA translation in live biology.
Lightning-Screen integrates Anima's T-Light technologies, TranslationLight and TranscriptLight, our primary screening assays used for the discovery of mRNA biology modulators. They capture millions of images that show the effect on mRNA biology of hundreds of thousands of compounds from our library.
The images captured during screening are automatically uploaded to the cloud to run through our proprietary High Content Analysis which selects the most promising hit compounds to move forward with. All these technologies feed and interact at every step with our MOAi, the underlying technology of Lightning-Compass, Anima’s AI based mechanism of action elucidation platform. AI driven MOA elucidation starts as early as hit generation, allowing us to de-risk compounds and progress them at an unprecedented success rate.
Computational biology + AI =
MOA elucidation with AI technology
Anima's MOAi technology has the potential to revolutionize drug discovery by enabling the identification of MOAs and molecular targets of hit compounds from phenotypic screening, a longstanding challenge in the field.
AI-driven MOA elucidation applied to mRNA regulation
mRNA Biology Modulators Pipeline
Anima wholly owned pipeline programs are in Immunology (Collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc mRNA biology modulators and mutation agnostic mKras mRNA biology modulators), and Neuroscience (Tau - Alzheimer's disease and Pain - Nav1.7 mRNA biology modulators). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.
| Indication | Target | Discovery |
Optimization |
IND enabling |
|
|---|---|---|---|---|---|
Immunology |
|||||
| Lung fibrosis | Collagen-1 | 1 | |||
| Multiple fibrosis | 2 | ||||
| Multiple fibrosis | 3 | ||||
| Undisclosed |  |
4 | |||
Oncology |
|||||
| Solid tumors | c-Myc | 5 | |||
| Lymphoma | 6 | ||||
| c-Myc tumors | 7 | ||||
| Neuroblastoma | Undisclosed | 8 | |||
| mKRAS tumors | mKRAS | 9 | |||
| Undisclosed | |
10 | |||
| Undisclosed | 11 | ||||
Neuroscience |
|||||
| Alzheimer | TAU | 12 | |||
| Pain | Nav 1.7 | 13 | |||
| Undisclosed | 14 | ||||
| Undisclosed |  |
15 | |||
| Undisclosed | 16 | ||||
| Huntington | mHTT | 17 | |||
| Undisclosed |  |
18 | |||
| Undisclosed | 19 | ||||
| Undisclosed | 20 | ||||
| Area | Indication | mRNA modulation | Target | Discovery |
Optimization |
IND enabling |
|
|---|---|---|---|---|---|---|---|
| Immunology | Lung fibrosis | Collagen-1 | 1 | ||||
| Multiple fibrosis | 2 | ||||||
| Multiple fibrosis | 3 | ||||||
| Undisclosed | |
4 | |||||
| Oncology | Solid tumors | c-Myc | 5 | ||||
| Lymphoma | 6 | ||||||
| c-Myc tumors | 7 | ||||||
| Neuroblastoma | Undisclosed | 8 | |||||
| mKRAS tumors | mKRAS | 9 | |||||
| Undisclosed | |
10 | |||||
| Undisclosed | 11 | ||||||
| Neuroscience | Alzheimer | TAU | 12 | ||||
| Pain | Nav 1.7 | 13 | |||||
| Undisclosed | 14 | ||||||
| Undisclosed | |
15 | |||||
| Undisclosed | 16 | ||||||
| Huntington | mHTT | 17 | |||||
| Undisclosed | |
18 | |||||
| Undisclosed | 19 | ||||||
| Undisclosed | 20 | ||||||
17 Scientific Collaborations
15 Peer Reviewed Publications
-
Measuring mRNA translation in neuronal processes and somata by tRNA-FRET
Nucleic Acids Res. 2020 ;46(6):e32 -
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53 -
DSCR1 is required for both axonal growth cone extension and steering
J Cell Biol. 2016; 23;213(4):451-62.
Coverage
News & Events
-
BIO International Convention 2023
When: Jun. 5th, 2023 - Jun. 8th, 2023
Where: Boston, MAAnima Biotech will be attending this year’s BIO International Convention. Our chief business officer, Kevin Pong, Ph.D., is looking forward to connecting with other industry experts. Additionnaly, he will give a corporate presentation on June. 5th at 3:45 P.M. EDT highlighting our unique approach to the discovery of small molecule mRNA drugs.
-
Oxford Global Discovery Europe
When: Jun. 6th, 2023 - Jun. 7th, 2023
Where: Berlin, GermanyAnima Biotech will participate in the Oxford Global Discovery Europe event as part of Identification and Validation of Novel Targets track of the Conference held in Berlin, Germany. Our head of discovery, Yoni Sheinberger, Ph.D., will give a presentation titled, “mRNA Lighting Platform | Discovery Of mRNA Biology Modulators and Their Mechanisms of Action,” on June 6th at 12:05 p.m. CST.
-
Locust Walk RNA Innovation Conference
When: May. 9th, 2023
Where: VirtualAnima Biotech has been invited to give a presentation during the Locust Walk RNA innovation event as part of the RNA-Targeting SMOLs track of the Conference held virtually on May 9th. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Advancing mRNA Lightning™ for the discovery of small molecule mRNA modulators and their mechanisms of action using p